These independent CME/CE activities are supported by an educational grant from

Curriculum II

Genentech BioOncology, OSI Oncology, and Pfizer Inc.

Curriculum I

Genentech BioOncology and OSI Oncology.
The Advanced Certificate Program in
Lung Cancer Management II
  1. Curriculum III
  2. Curriculum II
  3. Curriculum I
  4. Full Course List
Co-Chairs
faculty image
Roy S. Herbst, MD, PhD
  • Professor of Medicine and Cancer Biology
  • Department of Thoracic/Head and Neck Medical Oncology
  • The University of Texas M.D. Anderson Cancer Center
  • Houston, Texas
    • faculty image
    Corey J. Langer, MD, FACP
  • Professor of Medicine
  • Hematology-Oncology Division
  • Department of Medicine
  • University of Pennsylvania
  • Philadelphia, Pennsylvania
    • This free yearlong CME/CE program provides clinicians with up-to-date information about the management of lung cancer, featuring an expert faculty co-chaired by Roy S. Herbst, MD, PhD, and Corey J. Langer, MD, FACP, and a comprehensive curriculum of 24 web-based courses. Get timely and practical information that you can immediately use in caring for your patients with lung cancer.
  • Assess the diagnosis and staging of lung cancer utilizing knowledge of current and emerging lung cancer staging systems, tumor node metastasis classification, location of tumor, performance status, and surgical resectability in order to determine appropriate stage-specific treatment approaches.
  • Apply evidence-based guidelines to formulate treatment strategies for patients with early- and late-stage lung cancer.
  • Evaluate the appropriate use of chemotherapeutic agents in treatment strategies for lung cancer patients that improve outcomes through knowledge of their efficacy and safety.
  • Integrate targeted therapies into more-successful treatment regimens for lung cancer patients by assessing the efficacy and safety of these agents.
    • Chemotherapy—including paclitaxel, pralatrexate, and talotrexin
    • Chemoradiation
    • Neoadjuvant & adjuvant chemotherapy
    • Consolidative chemotherapy
    • Targeted therapies: gefitinib, erlotinib, bevacizumab, sunitinib, sorafenib, lonafarnib, vandetanib, cetuximab
    • Personalized therapy
    • Maintenance therapy
    • NCCN Treatment Guidelines
    • Risk factors and risk assessment
    • Screening and early detection
    • Diagnosis
    • Staging—using TNM classification of malignant tumors in NSCLC; using limited stage and extensive stages in SCLC
    • Bronchoalveolar carcinoma
    • PCI in lung cancer

    Target Audience

    This series of activities is designed for oncologists and other clinicians who specialize in and care for patients with lung cancer.

     

    Activity Goal

    The goal of these CME/CE activities is to examine current and emerging strategies for treating and managing patients with lung cancer.